US FDA Commissioner Scott Gottlieb said at a recent policy conference that chimeric antigen receptor T-cell (CAR-T) therapies may soon be relabeled for outpatient use, easing the cost of these new therapies for providers, while furnishing coverage under the Medicare Part B plan.
Find out more about the financial concerns for CAR-T therapies, the impact that outpatient CAR-T therapies would have on Medicare c. and what it means for both providers and for Medicare, in this essential article from Pink Sheet.
Find out more about the financial concerns for CAR-T therapies, the impact that outpatient CAR-T therapies would have on Medicare c. and what it means for both providers and for Medicare, in this essential article from Pink Sheet.
